Cardax, Inc.
CDXI
$0.00
$0.000.00%
| Weiss Ratings | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -1.93 | |||
| Price History | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -99.50% | |||
| 2-Year Total Return | -100.00% | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -99.91% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Dec 07, 2023 | |||
| 52-Week High Price (Date) | May 01, 2023 | |||
| Valuation | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 0.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 0.00 | |||
| Earnings Per Share (TTM) | -7.05 | |||
| Earnings Per Share Growth | -2.46% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 794.20K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 808 457 1400 | |||
| Address | 2800 Woodlawn Drive Honolulu, HI 96822 | |||
| Website | www.cardaxpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -584.76% | |||
| Profit Margin | -1,085.42% | |||
| Management Effectiveness | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -112.56% | |||
| Return on Equity | -- | |||
| Income Statement | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 500.70K | |||
| Total Revenue (TTM) | 500.70K | |||
| Revenue Per Share | $0.63 | |||
| Gross Profit (TTM) | 329.30K | |||
| EBITDA (TTM) | -2.89M | |||
| EBIT (TTM) | -2.93M | |||
| Net Income (TTM) | -5.43M | |||
| Net Income Avl. to Common (TTM) | -5.43M | |||
| Total Revenue Growth (Q YOY) | -26.75% | |||
| Earnings Growth (Q YOY) | -37.81% | |||
| EPS Diluted (TTM) | -7.05 | |||
| EPS Diluted Growth (Q YOY) | -21.62% | |||
| Balance Sheet | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 61.70K | |||
| Cash Per Share (Q) | $0.08 | |||
| Total Current Assets (Q) | 1.09M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -11.35M | |||
| Current Ratio (Q) | 0.087 | |||
| Book Value Per Share (Q) | -$14.15 | |||
| Total Assets (Q) | 1.38M | |||
| Total Current Liabilities (Q) | 12.45M | |||
| Total Debt (Q) | 5.40M | |||
| Total Liabilities (Q) | 12.73M | |||
| Total Common Equity (Q) | -11.35M | |||
| Cash Flow | CDXI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -6.10K | |||
| Cash from Financing (TTM) | 1.57M | |||
| Net Change in Cash (TTM) | 7.50K | |||
| Levered Free Cash Flow (TTM) | 349.20K | |||
| Cash from Operations (TTM) | -1.56M | |||
